Pipeline

Expanded Access Policy

To learn about our expanded access policy, click here.

Related Publications

Cardinale CJ, Wei Z, Panossian S, et al. Targeted resequencing identifies defective variants of decoy receptor 3 in pediatric-onset inflammatory bowel disease. Genes Immun. 2013;14(7):447-52.
https://www.ncbi.nlm.nih.gov/pubmed/23965943

Kugathasan S, Baldassano RN, Bradfield JP, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet. 2008;40(10):1211-5.
https://www.ncbi.nlm.nih.gov/pubmed/18758464

Steinberg MW, Shui JW, Ware CF, et al. Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners. Semin Immunopathol. 2009;31(2):207-21.
https://www.ncbi.nlm.nih.gov/pubmed/19495760

Wang J, Anders RA, Wang Y, et al. The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease. J Immunol. 2005;174(12):8173-82.
https://www.ncbi.nlm.nih.gov/pubmed/15944326

Lin WW, Hsieh SL. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol. 2011;81(7):838-47.
https://www.ncbi.nlm.nih.gov/pubmed/21295012